What is Sarepta Therapeutics, Inc.'s treasury stock?

Sarepta Therapeutics, Inc. (SRPT) reported treasury stock of $25.26M in Q1 2026.

What does treasury stock mean?

Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Sarepta Therapeutics, Inc. SRPT Treasury Stock

Treasury Stock at other companies

PfizerPFE

$115.19B+0.2%

Regeneron PharmaceuticalsREGN

$19.41B+19.7%

CRISPR TherapeuticsCRSP

$60K-3.2%

Ultragenyx PharmaceuticalRARE

$10M+32.2%

BridgeBio PharmaBBIO

$405.78M+25.5%

Arrowhead ResearchARWR

$53.19M—

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.82B-63.1%

Enterprise value$1.56B-67.2%

P/S0.8×—

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s treasury stock?: Sarepta Therapeutics, Inc. (SRPT) reported treasury stock of $25.26M in Q1 2026.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.